Russell J. Sanders

Associate Admitted to the Ontario Bar: 2017

Russell is a corporate lawyer dedicated to helping established and emerging companies achieve their growth and expansion plans. Backed by strong analytical and communication skills, Russell provides clients with comprehensive legal advice throughout the capital raising process. He leverages his business acumen to deliver results his clients can trust.

As a member of the firm's Capital Markets Group, Russell's practice focuses on corporate finance, mergers and acquisitions, securities and general corporate and commercial matters. Russell advises clients on equity and debt financings, stock exchange listings, reverse takeovers, initial public offerings and public company maintenance. He has been involved in a variety of transactions for clients across various industries, including mining, oil and gas, technology and the cannabis sector.

Representative Matters

Represented Maritime Resources Corp. (TSXV: MAE) in connection with the completion of a bought deal private placement of common shares and flow-through common shares for aggregate gross proceeds of approximately $8.7 million.

Represented Champignon Brands Inc., a ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer, in connection with its $15 million bought deal private placement. 

Represented Allied Properties Real Estate Investment Trust, a leading owner, manager and developer of distinctive urban workspace in Canada’s major cities and network-dense urban data centres in Toronto, in its completion of a $300 million debt offering of 3.131% series G senior unsecured debentures.

Advising AltMed Capital Corp., a ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer, on various aspects of its operations, including licensing matters, employment matters, tax structuring, joint ventures, services and leasing arrangements, and intellectual property commercialization.

Represented AltMed Capital Corp., a leading Canadian ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer, in connection with the sale of 100% of its issued and outstanding shares to Champignon Brands Inc., a company specializing in the formulation of a suite of medicinal mushrooms health products as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries.

Represented AltMed Capital Corp., a leading alternative medicine business incubator, IP aggregator and solutions provider, in connection with its acquisition of the Canadian Rapid Treatment Centre of Excellence Inc., a Canadian intravenous ketamine infusion therapy clinic. 

Represented Allied Properties Real Estate Investment Trust in its completion of a $400 million debt offering.

Acted for a Canadian entity, its Colombian subsidiary and the Colombian principals and employees of that entity in connection with the integration of the Colombian operations into the operations of a multinational operator in the federally legal cannabis industry.

Represented Thar Process, Inc., a U.S.-based provider of CO2 extraction and purification solutions for the hemp and cannabis industries, in the completion of a US$10 million private placement.

Represented MJ Innovation Capital Corp. (TSXV: MSMJ) in connection with its initial public offering.

Represented Harvest One Cannabis Inc. (TSXV: HVT), a global cannabis company in the health and wellness space, in its acquisition of biotechnology company Delivra Corp.

Advised CannTrust Holdings Inc. in respect of its short form prospectus offering of units for aggregate gross proceeds of $100,395,000.

Advised CannTrust Holdings Inc. in respect of its bought deal private placement of common shares for aggregate gross proceeds of $20,000,000. 

Represented a syndicate of agents led by Haywood Securities Inc. in connection with the initial public offering of SAIS Limited (formerly, Sarment Holding Limited) (TSXV: SAIS)

Represented Xanthic Biopharma Inc. (CSE: xTHC) in connection with the listing of its common shares on the Canadian Securities Exchange.

Represented Xanthic Biopharma Inc. (CSE: xTHC) in connection with a reverse takeover by Green Growth Brands Inc.

Selected Publications

Co-author with Sherri Altshuler and Jeffrey Merk, "CSA Highlights Need for Financial Interest Disclosure in Cannabis-Related M&A Transactions and Expresses Corporate Governance Concerns of Cannabis Issuers," Securities Law Bulletin, November 19, 2019.

Education

  • JD, University of Windsor, 2016
  • BA (Dean's Honor List), Western University, 2013

Expertise

Industries